Featured news from NHIVNA
HIV-related news from NAM
Vaccination could have important role in control of UK HCV epidemic among people who inject drugs
Michael Carter, 2016-06-30 07:00:00
A vaccine, even
with low efficacy, could lead to meaningful reductions in the incidence and
prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID), a
modelling study published in PLoS One
An international team of
investigators analysed the potential impact of three different vaccination
scenarios – low, moderate and high efficacy - on the HCV epidemic among PWID in
the UK over 20 and 40 years. A low efficacy vaccine (50% protection for five
years) would halve prevalence over 20 years if large numbers of PWID were
vaccinated each year. Vaccination rates needed to reduce incidence were lower
than those required for falls in prevalence, regardless of the potency of the
compared the impact of vaccination with HCV treatment on the UK epidemic,
calculating the number of vaccinations needed per case of treatment with new
direct acting agents (DAAs) to achieve the same effect.
suggests that even low efficacy HCV vaccines could have considerable impact;
potentially halving HCV prevalence and incidence among PWID in 40 years for
vaccine coverage levels comparable to what has been achieved for HBV [hepatitis
B virus] among PWID in the UK, 72% in 2013,” comment the investigators. “Our
modelling suggests that similar reductions in HCV prevalence or incidence could
be achieved with 4-16 or 2-11 times fewer treatments. Nonetheless, at current
HCV drug costs and even reduced costs, these ratios suggest that vaccination
could be a much cheaper strategy for reducing HCV transmission than scaling
Globally, 60% of
PWID have antibodies to HCV. This population is therefore a priority for HCV
suggested that therapy with new highly effective anti-HCV direct acting agents
could have a significant impact on new infections among high-risk populations.
However, these treatments are very expensive.
be an alternative prevention strategy and a partially effective vaccine could
be available soon.
therefore wanted to assess the potential usefulness of a vaccine for HCV
prevention and to compare its impact against new HCV therapies.
designed a model to determine the annual vaccination rates required to reduce
chronic HCV prevalence and incidence among PWID by 25%, 50% and 75% over 20 and
A treatment model
was also developed to determine the corresponding annual treatment rates needed
to achieve a similar impact. The investigators also calculated
vaccination-to-treatment ratio, i.e. the number of vaccinations needed per
treatment to achieve the same result.
model considered the potential impact of three scenarios:
A low efficacy vaccine – 50%
protection for five years.
A medium efficacy vaccine – 70%
protection for ten years.
A high efficacy vaccine – 90%
protection for 20 years.
scenario of the model was the current 40% prevalence of chronic HCV among PWID
in the UK.
rates of 100 per 1000 PWID could achieve reductions in prevalence of 35%, 65%
or 85% after 40 years for low, medium and high efficacy vaccines, respectively.
A vaccination rate below 50 per 1000 PWID would have only a modest impact (20%
reduction in 50 years) for a low efficacy vaccine, but could halve prevalence within
30 years with use of a high efficacy vaccine.
A low efficacy
vaccine would not halve prevalence over 20 years, but this result could be
achieved over 40 years with high vaccination rates (162 per 1000 PWID). Higher
efficacy vaccines required much lower annual vaccination rates to achieve this
Moderate and high
efficacy vaccines could achieve 75% reductions over 40 years with annual
vaccination rates of 138 and 79 per 1000 PWID, respectively.
vaccination levels needed to reduce HCV incidence over both 20 and 40 years was
smaller than that required to reduce prevalence. A moderately potent vaccine
required rates of 64 and 129 per 1000 PWID to halve incidence and prevalence,
respectively, over 20 years.
Comparison of the
impact of vaccination to treatment revealed that the vaccination rate needed to
achieve a 25% reduction in prevalence over 40 years was 3.4, 6 or 13 times
greater, depending on vaccine efficacy, than the treatment rate needed for the
same impact. These ratios increased for greater reductions in prevalence. But
the vaccination-to-treatment ratio was much lower when the impact on incidence
was considered. Only five vaccinations per treatment were needed to halve
incidence over 40 years for a moderately effective vaccine. Despite this, in
all scenarios considered, ratios favoured treatment, with the lowest ratio
(1.9) seen when considering the vaccination rate needed to reduce incidence by
25% over 20 years with a high efficacy product.
showed that the benefits of vaccination compared to treatment improved in PWID
populations with shorter duration of injecting or higher HCV prevalence.
“It is useful to
understand when the benefits of vaccination are heightened,” write the authors.
“HCV vaccination compares better to treatment for reducing HCV incidence than
reducing HCV prevalence, and when targeting higher-risk PWID. This suggests
that vaccination could be preferable to treatment in high prevalence settings
or among high-risk PWID subgroups, when treatment alone may not be suitable
because of the considerable risk of re-infection.”
The results of the
study are consistent with other research that modelled the potential impact of
a vaccine on the dynamics of the HCV epidemic among PWID in San Francisco.
The authors note
that the infrastructure for HCV vaccination is in place in the UK because of HBV
immunization campaigns and that high-levels of HBV vaccination coverage have
been achieved among PWID in some UK settings. An attraction of HCV vaccination
would be its likely cost, which could be approximately $500 per PWID, at least
50 times less than the current cost of HCV DAA therapy in high-income settings.
“It is possible
that treatment and vaccination could act in unison,” conclude the authors,
“with HCV uninfected PWID receiving vaccination and HCV infected PWID receiving
treatment, and possibly then vaccination.”